Table 1 Baseline characteristics of patients randomized for vitamin C (500 mg) or placebo supplement

Number

20

10

10

Sex (men/women)

14/6

9/1

5/5

Age at inclusion (years)

73 (57–84)

76 (70–84)

70 (57–84)

 MDS

9

5

4

 AML

7

2

5

 CMML

4

3

1

 0

11

5

6

 1

3

1

2

 2

3

2

1

 3

1

1

0

 4–7

2

1

1

IPSS-R score

5 (3.5–6.5)

4.5 (4–5.5)

5.5 (3.5–6.5)

Haemoglobin, g/dL

9.6 (7.1–14)

9.4 (7.1–14)

9.9 (7.6–12)

No. of blood transfusions in the study period

7 (0–33)

10 (0–33)

1 (0–18)

TET2 mutation, % of all (yes/no)

35% (7/13)

40% (4/6)

30% (3/7)

DNMT3A mutation, % of all (yes/no)

25% (5/15)

30% (3/7)

20% (2/8)

IDH2 mutation, % of all (yes/no)

10% (2/18)

20% (2/8)

0% (0/10)

Vitamin C, μmol/L^a

21 (5–73)

14 (5–37)

27 (7–73)

Iron, μmol/L^a

17 (2–33)

18 (2–33)

16 (5–32)

Transferrin, mg/dL^a

184 (116–257)

169 (116–237)

199 (148–257)

Ferritin level, μg/L^a

1624 (95–6244)

1993 (444–6244)

1254 (95–3632)